Helen Chew is an Oncology physician affiliated with University of California Davis Medical Center. OpenAlex indexes 147 publications with 9,859 citations (h-index 42); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2279 45th Street
Sacramento, CA 958172229
Telephone
916-734-5959Registry record last updated 22 Aug 2019.
Clinical trials
- Blood Glycan Biomarkers in Women With Stage IV Breast Cancer
Sponsor: University of California, Davis
- Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
Sponsor: University of California, Davis
- Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors
Sponsor: University of California, Davis
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
95.1%Aromatase Inhibitor52.2%Letrozole47%Anastrozole41%Exemestane12%Part D<11 patientsKinase inhibitor26.1%Kisqali62%Verzenio22%Ibrance16%Part D<11 patients+ 2 more classes in this area
Nervous system
4.9%Atypical Antipsychotic4.9%Olanzapine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2002–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Breast Cancer, Version 5.2025
Journal of the National Comprehensive Cancer Network
2025 - Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - NCCN Guidelines® Insights: Breast Cancer, Version 4.2023
Journal of the National Comprehensive Cancer Network
2023 - Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Marcio Malogolowkin, MD
University of California Davis Medical Center
Glenn Yiu, MD, PhD
University of California Davis Medical Center
Namita Sood, MD
University of California Davis Medical Center
Arta Monjazeb, MD, PhD
University of California Davis Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”